NCT05391893

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Emergency Department Atrial Fibrillation Oral Diltiazem Observation Protocol

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 444 (actual)
• Sponsor: Corewell Health South · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.

Conditions

• Atrial Fibrillation
• Atrial Flutter

Interventions

Type	Name	Description
DRUG	Oral	Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
DRUG	Intravenous drug	these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.

Timeline

• Start date: 2020-06-19
• Primary completion: 2023-04-01
• Completion: 2023-04-01
• First posted: 2022-05-26
• Last updated: 2024-12-27
• Results posted: 2024-12-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study